



PRISMASOL Renal Replacement Solution

Available in seven formulations for individualized patient therapy

PRISMASOL Solution provides the physician with a range of choices in response to each patient's specific condition. Available in seven formulas varying in calcium, potassium, bicarbonate and dextrose levels.

	Plasma*	Calcium Formulas			Calcium-Free Formulas			Dextrose-Free
		PRISMASOL BGK 4/2.5	PRISMASOL BGK 2/3.5	PRISMASOL BGK 0/2.5	PRISMASOL BGK 4/0/1.2	PRISMASOL BGK 2/0	PRISMASOL B22GK 4/0	PRISMASOL BK 0/0/1.2
Potassium K ⁺ (mEq/L)	3.5-5.0	4	2	0	4	2	4	0
Calcium Ca ²⁺ (mEq/L)	2.3-2.6 [†]	2.5	3.5	2.5	0	0	0	0
Magnesium Mg ²⁺ (mEq/L)	1.4-2.0	1.5	1	1.5	1.2	1	1.5	1.2
Sodium Na ⁺ (mEq/L)	135-145	140	140	140	140	140	140	140
Chloride Cl ⁻ (mEq/L)	100-108	113	111.5	109	110.2	108	120.5	106.2
Bicarbonate HCO ₃ ⁻ (mEq/L)	22-26	32	32	32	32	32	22	32
Lactate (mEq/L)	0.5-2.2	3	3	3	3	3	3	3
Dextrose (mg/dL)	70-110	100	100	100	100	100	100	0
Osmolarity (mOsm/L)	280-296	300	296	292	295	291	296	282
NDC Number		24571-105-06	24571-103-06	24571-108-06	24571-114-06	24571-102-06	24571-111-06	24571-113-06
Catalog Number		110242	110243	110240	110241	110244	115001	110239

*Ionized Calcium

Indications

PRISMASOL Renal Replacement Solution is indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolytes and acid-base imbalances. PRISMASOL Solution may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Important Risk Information

- PRISMASOL Renal Replacement Solution is contraindicated in patients with known hypersensitivities to this product.
- PRISMASOL Solution can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. The use of PRISMASOL Solutions containing dextrose may increase the risk for hyperglycemia in patients with impaired glucose tolerance. Patients may require initiation of or modification of antidiabetic therapy during treatment with PRISMASOL Solutions containing dextrose. Monitor blood glucose.

Press seal bag design



Incorrect use of the access ports or other restrictions to fluid flow will result in machine alarms. Ignoring and/or overriding repetitive alarms without resolving the originating cause might lead to incorrect patient weight loss and result in patient injury or death.

Please see enclosed full Prescribing Information.

For Customer Support call 800-525-2623.

References

*Luca, Bigatello M. et al. Critical Care Handbook of the Massachusetts General Hospital, 4th Edition, 2006

Baxter, Gambro and PrismaSol are trademarks of Baxter International Inc., or its subsidiaries.

USMP/MG140/14-0005(3) 500 11/16

Baxter